| DRC Phase I Unit | |||
| Therapeutic Area | Type of Study | Number of Volunteers | |
| 1. | hormon replacement | PK study/Renal impairment patients | 24 patients with renal insufficiency |
| 2. | potassium replacement | Bioequivalence | 24 HV |
| 3. | respiratory disease | Bioequivalence | 28 HV |
| 4. | psychiatry | Method validation for interaction studies | 18 HV |
| 5. | neurology | Bioequivalence | 24 HV |
| 6. | neurology | Bioequivalence | 24 HV |
| 7. | neurology | Bioequivalence | 24 HV |
| 8. | cardiovascular disease | Bioequivalence | 24 HV |
| 9. | antidepressant/ alcohol | Interaction study | 24HV |
| 10. | gastroenterology | Bioequivalence / food interaction | 24HV |
| 11. | gastroenterology | Bioequivalence | 32 HV |
| 12. | cardiovascular disease | Bioequivalence | 36 HV |
| 13. | Type 2 Diabetes | Bioequivalence | 24HV |
| 14. | anxiolitic/anxiolitic | Interaction study | 16 HV |
| 15. | cardiovascular disease | Bioequivalence / food interaction | 32 HV |
| 16. | cardiovascular disease | pharmacokinetic in elderly population | 24 HV, elderly healthy volunteers |
| 17. | cardiovascular disease | Bioequivalence / food interaction | 32 HV |
| 18. | neurology | Hepatic impairment study | 16 hepatic patients |
| 19. | rheumatology | Bioequivalence | 28 HV |
| 20. | respiratory disease | PK study/Hepatic patients | 24 hepatic patients |
| 21. | Type 2 Diabetes | Multiple dose; dose ranging study | 36 HV |
| 22. | oral contraceptive | Bioequivalence | 41 HV female |
| 23. | gastroenterology | Bioequivalence | 32 HV |
| 24. | gastroenterology | Bioequivalence | 32 HV |
| 25. | allergic disorders | Pharmacokinetic, pharmacodynamic study | 8 HV |
| 26. | gastroenterology | Multiple dose; dose ranging stduy | 60 HV |
| 27. | liver function diagnostic | PK study, single i.v. dose | 12 HV |
| 28. | rheumatology | Pharmacokinetic study | 11 hepatic patients, 12HV |
| 29. | musculosceletal | Interaction study | 16 HV |
| 30. | allergic disorders | Pharmacodinamic Study | 20 HV |
| 31. | allergic disorders | Bioequivalence study | 28 HV |
| 32. | infection disease | Hepatic impairment study | 32 hepatic patients, 16 HV |
| 33. | rheumatology | Dose ranging study | 5 RA patients |
| 34. | Insulin sensitizer / olanzapine | Interaction study | 54 HV |
| 35. | gastroenterology | Multiple dose; dose ranging study | 12 HV |
| 36. | T2 diabetes mellitus | Multiple dose; dose ranging study | 10 type II Diabetes patients |
| 37. | cardiovascular disease | Pharmacokinetic study | 19 patients with renal insufficiency |
| 38. | urology | Ascending single dose study | 37 HV |
| 39. | rheumatology | Interaction study | 4 RA patients |
| 40. | liver function diagnostic | PK study, multiple dose i.v. (different volume) | 24 HV |
| 41. | rheumatology | Ascending, multiple dose study | 5 RA patients |
| 42. | liver function diagnostic | PK cross-over study-i.v. | 12 HV |
| 43. | allergic disorders | Dose ranging, multiple dose | 60 allergic volunteers |
| 44. | urogenital disorder | ascending multiple dose | 24 HV |
| 45. | respiratory disease | Renal impairment study | 12 patients with renal insufficiency + 12 HV (group matching) |
| 46. | musculosceletal disorder | Bioequivalence | 52 HV |
| 47. | Sleep disorder | Liver impairment study | 13 hepatic patients + 13 HV (pair matching) |
| 48. | Type 2 Diabetes | single ascending dose | 11 diabetic patients |
| 49. | liver function diagnostic / Carbamazepine | Interaction study | 36 HV |
| 50. | Type 2 Diabetes | PK study / single dose | 18 patients with renal insufficiency + 4 HV (group matching) |
| 51. | musculosceletal disorder | Bioequivalence | 52 HV |
| 52. | urogenital disorder | Multiple ascending dose | 32 HV |
| 53. | liver function diagnostic | PK study for comparison and validation of different methods | 32 HV |
| 54. | Vaccines | Single ascending dose | 22 HV adults, 88 eldery HV |
| 55. | Type 2 Diabetes | PK study/Renal impairment | 23 renal patients |
| 56. | Diabetic nephropathy | PK study/Renal impairment | 18 renal patients, 14 HV |
| 57. | rheumatology | Exploratory study for kinetics for cholesterol flux | 5 RA patients, 5 HV |
| 58. | neurology | PK study/Liver impairment | 17 hepatic patients, 17 HV |
| 59. | psychiatry | PK study/Liver impairment | 7 hepatic patients, 4 HV |
| 60. | gastroenterology | PK study/Liver impairment | 13 hepatic patients, 7 HV |
| 61. | immunmodulator | PK study/Liver impairment | 24 hepatic patients, 8 HV |
| 62. | dermatology | Multiple ascending dose | 5 acne vulgaris patients |
| 63. | antiviral medication | PK study/Liver impairment | 7 hepatic patients, 8 HV |
| 64. | neurology | PK study/Liver impairment | 10 hepatic patients, 11 HV |
| 65. | immunmodulator | PK study/Renal impairment | 16 renal patients, 8 HV |
| 66. | Type 2 Diabetes | PK Study/Liver impairment | 13 hepatic patients, 5 HV |
| 67. | Vaccines | Multiple dose study | 140 HV |
| 68. | Gastroenterology | Multiple ascending dose | 6 UC patients |
| 69. | Dermatology | Multiple ascending dose | 6 Psoriatic patients |
| 70. | Rheumatology | Multiple ascending dose | 3 RA patients |
| 71. | Rheumatology | Multiple ascending dose | 3 RA patients |
| 72. | Gastroenterology | Single Ascending dose | 3 UC patients |
| 73. | Vitamin suplementation | PK study / single dose | 26 Vitamin D deficient adults |
| 74. | Alzheimer prevention | PK study / single ascending dose | 20 HV |
| 75. | Seizure | PK study / Single ascending dose | 6 renal patients |
| 76. | Vaccines | PK/PD Study | 36 HV |
| 77. | Gastroenterology | PK study | 2 UC patients |
| Note: HV= Healthy Volunteers | |||
| Clamp Studies on Healthy and Diabetic Patients | |||
| Year | Type of Study | Completed Clamps | |
| 2005 | Phase II. | 84 | |
| 2008 | Interaction study | 108 | |
| 2010 | Scientific | 100 | |
| 2011 | Scientific | 60 | |
| Total number of completed clamps | 352 | ||
